Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis

Annals of the Rheumatic Diseases
Jie ZhangJeffrey R Curtis

Abstract

To compare the coronary heart disease risk among patients with rheumatoid arthritis (RA) initiating common biologic disease-modifying antirheumatic drugs of different mechanisms. We conducted a retrospective cohort study of patients with RA enrolled in Medicare, a public health plan covering >90% of US residents 65 years or older, from 2006 to 2012 who (1) initiated a biologic, (2) had complete medical and pharmacy coverage for at least 12 months before biologic initiation and (3) were free of coronary heart disease at the time of initiation. We compared the incidence rates (IRs) of (1) acute myocardial infarction (AMI) and (2) a composite outcome of AMI or coronary revascularisation and used multivariable adjusted Cox regression models to examine the associations between the type of biologic and the two outcomes. We identified 47 193 eligible patients with RA with mean age 64 (SD 13) years; 85% were women. Crude IRs for AMI ranged from 5.7 to 8.8 cases per 1000 person-years (PYs). AMI risk was significantly elevated among antitumour necrosis factor (anti-TNF) initiators overall (adjusted HR (aHR) 1.3; 95% CI 1.0 to 1.6) and individually among etanercept (aHR 1.3; 95% CI 1.0 to 1.8) and infliximab (aHR 1.3; 95% CI 1.0 to 1.6) c...Continue Reading

References

Mar 12, 2003·Circulation·Daniel H SolomonGary C Curhan
Dec 1, 2006·Arthritis and Rheumatism·Daniel H SolomonSebastian Schneeweiss
Feb 28, 2007·Annals of the Rheumatic Diseases·Loreto CarmonaUNKNOWN BIOBADASER and EMECAR Groups
Mar 8, 2008·Arthritis Research & Therapy·Antonio NaranjoUNKNOWN QUEST-RA Group
Nov 28, 2008·Arthritis and Rheumatism·J Antonio Aviña-ZubietaDiane Lacaille
Nov 27, 2010·Annals of the Rheumatic Diseases·Jeffrey D GreenbergUNKNOWN CORRONA Investigators
Sep 3, 2011·Arthritis Research & Therapy·Michael H SchiffRonald F van Vollenhoven
Jun 30, 2012·Pharmacoepidemiology and Drug Safety·Sarah L CutronaJerry H Gurwitz
Dec 11, 2013·Biologics : Targets & Therapy·Sylvain MathieuMartin Soubrier
Oct 11, 2014·Seminars in Arthritis and Rheumatism·Jeffrey R CurtisUNKNOWN Actemra Pharmacoepidemiology Board
Nov 25, 2014·The Cochrane Database of Systematic Reviews·Philip MassonAngela C Webster
Oct 8, 2015·American Journal of Epidemiology·Shia T KentPaul Muntner

❮ Previous
Next ❯

Citations

Dec 3, 2016·Arthritis Research & Therapy·Jenny HumphreysDeborah Symmons
Mar 15, 2018·Pharmacoepidemiology and Drug Safety·Fenglong XiePaul Muntner
May 31, 2018·Current Rheumatology Reports·Eun Ha KangSeoyoung C Kim
Jul 12, 2019·Nature Reviews. Rheumatology·Lyn D FergusonNaveed Sattar
Aug 2, 2019·PloS One·Benjamin CastagnéMartin Soubrier
May 14, 2020·Expert Opinion on Biological Therapy·Sei MuraokaToshihiro Nanki
May 13, 2018·International Journal of Molecular Sciences·Sophie SteelandRoosmarijn E Vandenbroucke
Apr 30, 2020·Journal of Clinical Medicine·Maria Antonietta BarbieriEdoardo Spina
Jan 29, 2017·Current Atherosclerosis Reports·Jaana HartialaHooman Allayee
Aug 20, 2017·Clinical Rheumatology·Maria-Antonietta D'AgostinoGianfranco Ferraccioli
Jan 9, 2019·Frontiers in Cardiovascular Medicine·Elena BartoloniRoberto Gerli
Jul 10, 2018·Rheumatology·Clément LahayeMartin Soubrier
Jun 29, 2017·Expert Opinion on Biological Therapy·Juan D CañeteRaimon Sanmartí
Apr 14, 2018·Drugs & Aging·Martin SoubrierZuzana Tatar
Dec 20, 2019·Rheumatology and Therapy·Daniel J DeMizio, Laura B Geraldino-Pardilla
Oct 23, 2020·Pharmacoepidemiology and Drug Safety·Michael M Ward
Jul 2, 2019·Current Vascular Pharmacology·George E FragoulisElena Nikiphorou
Oct 30, 2020·Frontiers in Immunology·Daniella Muallem SchwartzNehal N Mehta
Mar 7, 2021·Expert Review of Clinical Immunology·George A KarpouzasSarah R Ormseth
May 1, 2021·International Journal of Molecular Sciences·Rosaria Vincenza GiglioManfredi Rizzo
May 22, 2021·Journal of Inflammation Research·George E FragoulisGeorge D Kitas

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.